Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram.

Chao TF, Lu TM, Lin YJ, Tsao HM, Chang SL, Lo LW, Hu YF, Tuan TC, Hsieh MH, Chen SA.

PLoS One. 2013 Aug 7;8(8):e71675. doi: 10.1371/journal.pone.0071675. eCollection 2013.

2.

Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography.

Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ.

Int J Cardiol. 2011 Dec 1;153(2):135-40. doi: 10.1016/j.ijcard.2011.06.120. Epub 2011 Jul 26.

PMID:
21794936
3.

Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure.

Hsu CP, Lin SJ, Chung MY, Lu TM.

Atherosclerosis. 2012 Dec;225(2):504-10. doi: 10.1016/j.atherosclerosis.2012.09.040. Epub 2012 Oct 10.

PMID:
23092827
4.

[Effect of asymmetrical dimethylarginine for predicting pro-thrombotic risk in atrial fibrillation].

Lao MC, Liu LJ, Luo CF, Lu GH, Zhai YS, Chen XL, Gao XR.

Zhonghua Yi Xue Za Zhi. 2016 Jul 12;96(26):2059-63. doi: 10.3760/cma.j.issn.0376-2491.2016.26.005. Chinese.

PMID:
27468617
5.

Asymmetric dimethylarginine concentration and recurrence of atrial tachyarrythmias after catheter ablation in patients with persistent atrial fibrillation.

Yang L, Xiufen Q, Shuqin S, Yang Y, Ying S, Yanwei Y, Wei F, Dechun Y.

J Interv Card Electrophysiol. 2011 Nov;32(2):147-54. doi: 10.1007/s10840-011-9588-7. Epub 2011 May 19.

PMID:
21594627
6.

Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?

Roldán V, Marín F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M, Vicente V, Lip GY.

Thromb Haemost. 2013 May;109(5):956-60. doi: 10.1160/TH13-01-0054. Epub 2013 Mar 21.

PMID:
23572113
7.

Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.

Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Pinsky DJ, Marmur JD.

Coron Artery Dis. 2009 Mar;20(2):112-7. doi: 10.1097/MCA.0b013e328323982f.

PMID:
19240644
8.

Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease.

Lu TM, Chung MY, Lin CC, Hsu CP, Lin SJ.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1566-72. doi: 10.2215/CJN.08490910. Epub 2011 Jun 3.

9.

Atrial Fibrillation Is Associated with a Marker of Endothelial Function and Oxidative Stress in Patients with Acute Myocardial Infarction.

Stamboul K, Lorin J, Lorgis L, Guenancia C, Beer JC, Touzery C, Rochette L, Vergely C, Cottin Y, Zeller M.

PLoS One. 2015 Jul 9;10(7):e0131439. doi: 10.1371/journal.pone.0131439. eCollection 2015.

10.

The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: role of incorporating PR prolongation.

Chan YH, Yiu KH, Lau KK, Yiu YF, Li SW, Lam TH, Lau CP, Siu CW, Tse HF.

Atherosclerosis. 2014 Dec;237(2):504-13. doi: 10.1016/j.atherosclerosis.2014.08.026. Epub 2014 Aug 30.

PMID:
25463082
11.

Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.

Roldán V, Vílchez JA, Manzano-Fernández S, Jover E, Gálvez J, Puche CM, Valdés M, Vicente V, Lip GY, Marín F.

Stroke. 2014 Mar;45(3):696-701. doi: 10.1161/STROKEAHA.113.003338. Epub 2014 Feb 11.

12.

Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow.

Selcuk MT, Selcuk H, Temizhan A, Maden O, Ulupinar H, Baysal E, Ozeke O, Sasmaz A.

Coron Artery Dis. 2007 Nov;18(7):545-51.

PMID:
17925608
13.

Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.

Kornej J, Hindricks G, Kosiuk J, Arya A, Sommer P, Husser D, Rolf S, Richter S, Piorkowski C, Gaspar T, Lip GY, Bollmann A.

Circ Arrhythm Electrophysiol. 2013 Oct;6(5):868-74. doi: 10.1161/CIRCEP.113.000869. Epub 2013 Sep 18.

14.

High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation.

Roldán V, Marín F, Díaz J, Gallego P, Jover E, Romera M, Manzano-Fernández S, Casas T, Valdés M, Vicente V, Lip GY.

J Thromb Haemost. 2012 Aug;10(8):1500-7. doi: 10.1111/j.1538-7836.2012.04812.x.

15.

CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation.

Letsas KP, Efremidis M, Giannopoulos G, Deftereos S, Lioni L, Korantzopoulos P, Vlachos K, Xydonas S, Kossyvakis C, Sideris A.

Europace. 2014 Feb;16(2):202-7. doi: 10.1093/europace/eut210. Epub 2013 Jun 28.

PMID:
23813452
16.

Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.

Tu HT, Campbell BC, Meretoja A, Churilov L, Lees KR, Donnan GA, Davis SM.

Cerebrovasc Dis. 2013;36(4):273-80. doi: 10.1159/000353670. Epub 2013 Oct 16.

PMID:
24135809
17.

Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation.

Ehrlich JR, Kaluzny M, Baumann S, Lehmann R, Hohnloser SH.

Clin Res Cardiol. 2011 Nov;100(11):1029-36. doi: 10.1007/s00392-011-0337-9. Epub 2011 Jul 3.

PMID:
21725858
18.

Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.

Schnabel RB, Maas R, Wang N, Yin X, Larson MG, Levy D, Ellinor PT, Lubitz SA, McManus DD, Magnani JW, Atzler D, Böger RH, Schwedhelm E, Vasan RS, Benjamin EJ.

Am Heart J. 2016 Jun;176:100-6. doi: 10.1016/j.ahj.2016.03.007. Epub 2016 Mar 17.

19.

Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.

Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Eyileten T, Gezer M, Verim S, Oguz Y, Vural A, Ortiz A, Johnson RJ, Covic A, Yilmaz MI.

Int Urol Nephrol. 2016 Jul;48(7):1129-36. doi: 10.1007/s11255-016-1271-6. Epub 2016 Mar 23.

PMID:
27007614
20.

ADMA, subclinical changes and atrial fibrillation in the general population.

Ramuschkat M, Appelbaum S, Atzler D, Zeller T, Bauer C, Ojeda FM, Sinning CR, Hoffmann B, Lackner KJ, Böger RH, Wild PS, Münzel T, Blankenberg S, Schwedhelm E, Schnabel RB; Gutenberg Health Study Investigators.

Int J Cardiol. 2016 Jan 15;203:640-6. doi: 10.1016/j.ijcard.2015.05.102. Epub 2015 May 19.

PMID:
26580348

Supplemental Content

Support Center